<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159781">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01937494</url>
  </required_header>
  <id_info>
    <org_study_id>AK/13-03-34/4235</org_study_id>
    <nct_id>NCT01937494</nct_id>
  </id_info>
  <brief_title>Bronchial Hyperreactivity During Histamine Passive Exposure</brief_title>
  <official_title>Are Technicians Showing Bronchial Hyperreactivity Able to Safely Perform Bronchial Provocation Tests?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Saint Pierre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Saint Pierre</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bronchial hyperresponsiveness consists in excessive response to bronchial stimuli.Bronchial
      challenge test is used to confirm/exclude asthma (metacholine or histamine).Protection are
      used to avoid passive exposure of the technicians performing the test, despite the absence
      of evidence that they could develop a bronchoconstriction even if they suffer from BHR.The
      purpose of the study is to determine if patients with a high level of bronchial
      hyperreactivity and exposed passively to histamine during a bronchial challenge, are
      developing a bronchoconstriction, when placed in the same conditions that the technicians
      performing these tests.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bronchial hyperresponsiveness (BHR) consists in excessive response to bronchial
      stimuli.Bronchial challenge test is used to confirm/exclude asthma.BHR is also present in
      other diseases such as allergic rhinitis, Chronic Obstructive pulmonary disease,heart
      failure..

      Thes test is performed with metacholine or histamine with spirometric documented response to
      incremental doses.Protection are used to avoid passive exposure of the technicians
      performing the test, despite the absence of evidence that they could develop a
      bronchoconstriction if they suffer from BHR.

      The purpose of the study is to determine if patients, newly diagnosed with a high level of
      bronchial hyperreactivity and exposed passively to histamine during a bronchial challenge,
      are reacting to histamine when placed in the same conditions that the technicians performing
      these tests.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>spirometric values in patients exposed passively to histamine during BHR challenge</measure>
    <time_frame>1 hour</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Asthma</condition>
  <condition>Bronchial Hyperresponsiveness</condition>
  <arm_group>
    <arm_group_label>asthma patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients who show a positive response at the first dos of histamine challenge test will be enrolled</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>histamine-benzylic alcohol (magistral preparation)</intervention_name>
    <description>passive exposure to histamine during a bronchial hyperresponsiveness challenge</description>
    <arm_group_label>asthma patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients with positive histamine challenge test (first dose)

        Exclusion Criteria:

          -  other active respiratory disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Bruyneel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU ST Pierre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Gabrovska, MD</last_name>
    <phone>003225353368</phone>
    <email>maria_gabrovska@stpierre-bru.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Bruyneel, MD</last_name>
    <phone>003225354219</phone>
    <email>marie_bruyneel@stpierre-bru.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>service de pneumologie, CHU St Pierre</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>maria gabrovska, MD</last_name>
      <email>maria_gabrovska@stpierre-bru.be</email>
    </contact>
    <investigator>
      <last_name>maria Gabrovska, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>August 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Saint Pierre</investigator_affiliation>
    <investigator_full_name>Marie Bruyneel</investigator_full_name>
    <investigator_title>CCA, pneumologie</investigator_title>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>bronchial hyperresponsiveness</keyword>
  <keyword>histamine challenge test</keyword>
  <keyword>spirometry</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Bronchial Hyperreactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Histamine</mesh_term>
    <mesh_term>Histamine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
